- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | Cinclus Pharma Holding AB: Cinclus Pharma has completed all patient visits in Phase III HEEALING1 study; topline results expected in Q4 2026 | 130 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing next-generation treatments for acid-related diseases, announced today that the last patient has completed the final... ► Artikel lesen | |
| 02.09. | Cinclus Pharma Holding AB: Cinclus Pharma completes the treatment period in the Phase III HEEALING1 study - topline results expected in Q4 2026 | 171 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a clinical pharmaceutical company developing next-generation treatments for acid-related diseases, announces today that the last patient in the Phase III HEEALING1... ► Artikel lesen | |
| 19.08. | Earnings Call: Cinclus Pharma meldet Verlust für Q2 - entscheidende Studiendaten rücken näher | 1 | Investing.com Deutsch | ||
| 19.08. | Cinclus Pharma Holding AB: Interim report Q2 2026 - HEEALING1 Fully Enrolled - Topline Results Expected in Q4 2026 | 224 | GlobeNewswire (Europe) | "Enrollment in our first Phase III trial, HEEALING1, is now completed as planned, and we are entering the final step before readout, expected in the fourth quarter of this year. With a robust clinical... ► Artikel lesen | |
| 02.07. | Cinclus Pharma Holding AB: Cinclus Pharma has Reached Enrollment Target in Phase III HEEALING1 Study - Topline Results Expected Q4 2026 | 285 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a clinical pharmaceutical company developing next-generation treatments for acid-related diseases, today announced that the randomization target has been reached in... ► Artikel lesen | |
| 03.06. | Cinclus Pharma Holding AB: Cinclus Pharma Achieves Key Phase III Milestone: Last Patient Screened in HEEALING1 Study | 264 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases, today announced the successful completion of screening of... ► Artikel lesen | |
| 21.05. | Cinclus Pharma Holding AB: Resolutions at the Annual General Meeting in Cinclus Pharma Holding AB (publ) on 21 May 2026 | 245 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ) (Reg. No. 559136-8765) today, on 21 May 2026, held its Annual General Meeting. The complete proposals have previously been published and are available at the company's... ► Artikel lesen | |
| 19.05. | Cinclus Pharma: Erster Umsatz im ersten Quartal 2026 sorgt für Kursanstieg | 2 | Investing.com Deutsch | ||
| CINCLUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 13.05. | Cinclus Pharma Holding AB: Interim report January-March 2026 - Phase III study approaching full enrollment | 437 | GlobeNewswire (Europe) | "Patient enrollment in our first Phase III study has continued to progress well and we have good visibility on the timeline with expected topline results in the fourth quarter of this year. The strengthened... ► Artikel lesen | |
| 23.02. | Cinclus Pharma Holding AB: Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US - Positive for the Company's Phase III Program | 292 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for acid-related gastrointestinal diseases, today announces that the FDA has clarified... ► Artikel lesen | |
| 18.02. | Cinclus Pharma Holding AB: Year-end report - Advancing toward Phase III readout | 269 | GlobeNewswire (Europe) | "The past year was marked by significant progress for Cinclus Pharma. Our first Phase III study has had a promising start, and we expect to present topline results during the second half of the year.... ► Artikel lesen | |
| 13.02. | Cinclus Pharma Holding AB: Cinclus Pharma receives positive assessment of its nonclinical development plan from the FDA | 222 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases, today announced that the US Food and Drug Administration... ► Artikel lesen | |
| 10.02. | Cinclus Pharma Holding AB: Cinclus Pharma receives regulatory support - EMA provides positive feedback on CMC for linaprazan glurate | 252 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases, today announced that the European Medicines Agency... ► Artikel lesen | |
| 19.01. | Cinclus Pharma Holding AB: Resolutions at the Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) on 19 January 2026 | 466 | GlobeNewswire (Europe) | Cinclus Pharma Holding AB (publ) (Reg. No. 559136-8765) today, on 19 January 2026, held an Extraordinary General Meeting.The Extraordinary General Meeting resolved, in accordance with the Nomination... ► Artikel lesen | |
| 08.12.25 | Cinclus Pharma Holding AB: Cinclus Pharma recruits Magnus Christensen as new CFO | 363 | GlobeNewswire (Europe) | Cinclus Pharma today announces that Magnus Christensen has been recruited as CFO after Maria Engström, at her own request, has chosen to leave her role. He comes most recently from a role as CFO at... ► Artikel lesen | |
| 20.11.25 | Cinclus Pharma Holding AB: A positive start to the Phase III study | 300 | GlobeNewswire (Europe) | "Cinclus Pharma has now entered late-stage clinical development following the initiation of its first Phase III study, and patient recruitment has so far progressed well. Topline results are expected... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 50,13 | +0,22 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| GSK | 22,840 | 0,00 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK nach Studiendaten für das Krebs-Konjugat Risvutatug Rezetecan mit einem Kursziel von 2500 Pence auf "Buy" belassen.... ► Artikel lesen | |
| IAMBIC THERAPEUTICS | 14,520 | -1,02 % | Biotech an der Börse: Iambic-IPO bringt 150 Millionen USD für Krebsmedikamente | Das US-Biotechunternehmen Iambic setzt bei neuen Krebsmedikamenten auf künstliche Intelligenz. Mit dem frischen Börsenkapital will es klinische Studien voranbringen und seine Forschungstechnik ausbauen.... ► Artikel lesen | |
| BAYER | 44,120 | -0,20 % | Bayer: Wird Nubeqa zum größten Medikament der Firmengeschichte? | Auf dem Krebskongress ESMO stehen Zwischendaten zu Bayers Prostatakrebsmittel Nubeqa an. Die BofA rechnet mit einem klaren Erfolg und traut dem Medikament den Rekord in der Konzerngeschichte zu. Bayer... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,130 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten | ||
| GENERATE BIOMEDICINES | 12,800 | +0,08 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| LB PHARMACEUTICALS | 39,460 | +0,10 % | Stifel reiterates Buy rating on LB Pharmaceuticals stock at $53 | ||
| KARDIGAN | 12,740 | 0,00 % | Baird stuft Kardigan mit "Outperform" ein - Kursziel 43 US-Dollar | ||
| OMNIAB | 4,770 | -0,21 % | OmniAb auf der LD Micro Konferenz: Lizenzgebühren, Skalierung und Geduld im Fokus | ||
| BRIGHT MINDS BIOSCIENCES | 52,50 | -0,36 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen | |
| MERCK KGAA | 144,80 | -1,06 % | Eli Lillys Umsatzsprung, Mercks 11,3-Milliarden-Dollar-Deal: Wie Zelltherapien in die Wachstumsstory der Pharmabranche passen | ||
| NOVO NORDISK | 35,300 | +0,44 % | Novo Nordisk muss zittern: Eli Lilly vor Milliardenchance: Neue Abnehmpille nimmt wichtige EU-Hürde! | Eli Lillys Abnehmpille Foundayo nimmt eine wichtige EU-Hürde. Die mögliche Zulassung verschärft den Milliardenwettbewerb mit Novo Nordisk Enthaltene Werte: US5324571083,DK0062498333Den vollständigen... ► Artikel lesen | |
| DERMAPHARM | 38,700 | 0,00 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| APNIMED | 18,540 | +0,05 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen |
Das Unternehmen CINCLUS PHARMA HOLDING AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 1,014 Euro und damit -4,88 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CINCLUS PHARMA HOLDING AB finden Sie auf Wallstreet Online.